MedTrace Logo

Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

NCT05896969 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-06-21

No results posted yet for this study

Summary

This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C. The study will be divided into two parts:

* SAD cohorts
* MAD cohorts

Conditions

  • Elevated Low-Density Lipoprotein Cholesterol

Interventions

DRUG

SNK-396 - SAD cohort

A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.

DRUG

SNK-396 - MAD Cohort

Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.

Sponsors & Collaborators

  • SynerK Pharmatech (Suzhou) Limited

    collaborator UNKNOWN

  • Syneos Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2024-02-23
Completion
2024-02-23

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05896969 on ClinicalTrials.gov